Wednesday, August 27, 2014
FAIRFIELD-SUISUN, CALIFORNIA
99 CENTS

Merck to pay $3.85B for hepatitis C drug developer

Merck

FILE - This Thursday, Feb. 28, 2013 file photo shows a patch with the Merck logo on a scientist's lab coat in West Point, Pa. Merck on Monday, June 9, 2014 announced it will spend nearly $4 billion for Idenix Pharmaceuticals with a per-share bid that more than triples the hepatitis C drug developer’s latest closing price. (AP Photo/Matt Rourke, File)

By
June 10, 2014 |

TRENTON, N.J. — Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck’s experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.

The price for the deal announced Monday — a per-share bid more than triple Friday’s closing price for Cambridge, Massachusetts-based Idenix — seems high. However, the latest hepatitis C medicines command very high prices, the number of patients keeps rising and Merck was bidding against rivals.

Hepatitis C has become one of the hottest categories in drug research as companies race to develop a combination therapy without injections and debilitating side effects. Some have had their promising candidates fail after extensive testing, due to dangerous side effects, but Gilead Sciences Inc. is already raking in billions of dollars from its groundbreaking new drug, Sovaldi.

Merck, based in Whitehouse Station, New Jersey, said it will spend $24.50 in cash for each Idenix share. Idenix closed at $7.23 on Friday, then more than tripled at Monday’s opening bell.

The boards of both companies have approved the deal, which should close in the third quarter.

“Idenix has established a promising portfolio of hepatitis C candidates based on its expertise in (certain) technologies,” Merck’s research head, Dr. Roger Perlmutter, said in a statement.

Three Idenix experimental drugs have reached human testing and one, samatasvir, is in mid-stage testing. It’s in a new drug class called NS5A inhibitors, which disrupt various stages of the virus life cycle. Two other drugs, known as IDX21437 and IDX21459, are in a class called nucleotide prodrugs, which stop the virus from producing genetic material needed to copy itself.

Merck has been testing two drugs together, MK-5172 and MK-8742, that the Food and Drug Administration has deemed a breakthrough therapy. Merck will soon start late-stage testing of the two drugs together and presumably will study them in combinations with the Idenix drugs.

About 4.4 million Americans and an estimated 170 million people worldwide have chronic hepatitis C, the leading cause of liver cancer and, in wealthy countries, the top reason for liver transplants. In the U.S., it kills more than 16,000 people a year.

While most people infected don’t know it because there are no obvious symptoms, a growing number have been identified and started treatment in the last few years as more effective medicines have been approved. That number is expected to grow as the U.S. population ages and patients infected decades ago through intravenous drug use, or from blood transfusions before the early 1990s, are diagnosed.

Merck has been a major player in hepatitis C since acquiring Schering-Plough in 2009. Back then, treatment was limited to twice-a-day pills called ribavirin and self-injections of a long-acting, synthetic form of immune system protein interferon. Treatment often lasted 48 weeks, only about 40 percent of patients were cured, and flu-like symptoms and other side effects of the interferon kept many patients from completing treatment.

In 2011, the FDA approved two drugs in a class called protease inhibitors, Merck’s Victrelis and Incivek from Vertex Pharmaceuticals. Those are taken with ribavirin and interferon, work by blocking an enzyme needed for copying the virus, and boost the cure rate to about 75 percent. But they require patients to take a dozen pills a day, and still endure flu-like side effects.

Last December, the FDA approved Gilead’s once-a-day pill Sovaldi, which cures 80 percent to 90 percent of patients, without the interferon injections and side effects.

Physicians quickly embraced it, and Sovaldi racked up more than $2 billion in sales in its first full quarter on sale, considered the best new drug launch in history. That’s mainly because of Sovaldi’s high price, about $1,000 per pill, or $84,000 for a 12-week treatment course, which continues to draw criticism from patients, insurers and government.

Sovaldi appears poised to dominate the hepatitis C market, greatly outselling Johnson & Johnson’s Olysio, approved about the same time. But there’s plenty of room for Merck and others because Sovaldi can’t be taken by some patients with multiple illnesses or certain hepatitis C subtypes.

In afternoon trading, Idenix shares climbed $16.76 to $23.99. Merck shares slipped 5 cents to $57.80.

Shares of another hepatitis C drug developer, Achillion Pharmaceuticals Inc., now seen as a potential takeover target, climbed 58 percent to $4.55.

 

The Associated Press

The Associated Press

LEAVE A COMMENT

Discussion | No comments

The Daily Republic does not necessarily condone the comments here, nor does it review every post. Read our full policy

.

Solano News

Ryde Hotel: A speakeasy from the past

By Susan Winlow | From Page: A1 | Gallery

 
Walnut Grove shows a bit of historic Japan

By Susan Winlow | From Page: A1 | Gallery

Walnut Grove: Fun facts, things to see

By Susan Winlow | From Page: A1

 
Solano County supervisors get raise

By Barry Eberling | From Page: A2

Solano supervisors declare quake state of emergency

By Barry Eberling | From Page: A3

 
Solano helps after Napa quake

By Barry Eberling | From Page: A3 | Gallery

Weather for Aug. 27, 2014

By Daily Republic | From Page: B3

 
 
Solano promotes hand washing

By Barry Eberling | From Page: A5, 1 Comment

 
Solano College to host college transfer fair

By Susan Winlow | From Page: A6

 
Golf tournament to benefit college sport’s teams

By Susan Winlow | From Page: A6

Man steals car from Fairfield resident

By Barry Eberling | From Page: A6, 4 Comments

 
Learn about local travel opportunities

By Amy Maginnis-Honey | From Page: A6

 
Pierce Brosnan thriller kicks off week’s new films

By Amy Maginnis-Honey | From Page: A7

 
Vacaville OK’s 20-percent reduction in water use

By Ryan McCarthy | From Page: A8

 
Museum guild schedules trip to historic San Francisco home

By Amy Maginnis-Honey | From Page: A8

 
3 die in I-680 crash; 2 from Vacaville

By Ian Thompson | From Page: A9

 
Suisun City police log: Aug. 25, 2014

By Glen Faison | From Page: A12

 
Fairfield police log: Aug. 24, 2014

By Glen Faison | From Page: A12

Fairfield police log: Aug. 23, 2014

By Glen Faison | From Page: A12

 
Suisun City police log: Aug. 24, 2014

By Glen Faison | From Page: A12

Suisun City police log: Aug. 23, 2014

By Glen Faison | From Page: A12

 
Fairfield police log: Aug. 25, 2014

By Susan Hiland | From Page: A12

.

US / World

UN panel: Global warming human-caused, dangerous

By The Associated Press | From Page: B8

 
Obama defends handling of veterans affairs issues

By The Associated Press | From Page: B8

Arab strikes in Libya show impatience with US

By The Associated Press | From Page: B8

 
AP sources: US surveillance planes fly over Syria

By The Associated Press | From Page: B8

Napa quake stirs clamor for warning system

By The Associated Press | From Page: B8

 
American woman held hostage in Syria

By The Associated Press | From Page: B8

Putin and Poroshenko meet for bilateral talks

By The Associated Press | From Page: B8

 
Group files petition to idle coastal nuke plant

By The Associated Press | From Page: B8

Israel, Hamas agree to open-ended Gaza cease-fire

By The Associated Press | From Page: B8

 
Los Angeles schools halt iPad deal amid criticism

By The Associated Press | From Page: B8

Report finds 1,400 children exploited in UK town

By The Associated Press | From Page: B8

 
Police: Slain woman ID’d ex-deputy as her attacker

By The Associated Press | From Page: B8

Officials: Instructor accidentally killed by girl

By The Associated Press | From Page: B8

 
Judges blast Indiana, Wisconsin gay marriage bans

By The Associated Press | From Page: B8

.

Opinion

How to reduce taxes without busting the budget

By Ramesh Ponnuru | From Page: A11

 
Abandoned carts are everyone’s responsibility

By Letter to the Editor | From Page: A11, 1 Comment

Editorial cartoons for Aug. 27, 2014

By Daily Republic Syndicated Content | From Page: A11

 
Question of the week: Is US policy on hostages correct?

By Daily Republic | From Page: A11

Obama risks alienating Latinos from Dems

By Thomas Elias | From Page: A11

 
.

Living

Today in History: Aug. 27, 2014

By The Associated Press | From Page: A2

 
Community Calendar: Aug. 27, 2014

By Susan Hiland | From Page: A2

We were good parents. Why won’t our adult children help us out?

By Kathy Mitchell and Marcy Sugar | From Page: B6

 
Horoscopes: Aug. 27, 2014

By Holiday Mathis | From Page: B6

Banishing the blues with healthy blueberry muffins

By Sara Moulton | From Page: B7

 
Choosing chutney

By Mcclatchy-Tribune News Service | From Page: B7

.

Entertainment

TVGrid

By Daily Republic Syndicated Content | From Page: A7

 
Women talk about sports on CBS Sports Network

By The Associated Press | From Page: A7

Miley Cyrus’ date wanted by Oregon police

By The Associated Press | From Page: A7

 
NBC’s Emmycast logs robust 15.6 million viewership

By The Associated Press | From Page: A7

.

Sports

US teen Bellis, 15, stuns Cibulkova at US Open

By The Associated Press | From Page: B1

 
Raiders CB DJ Hayden to start season on PUP list

By The Associated Press | From Page: B1

49ers prepare for possible Aldon Smith suspension

By The Associated Press | From Page: B1

 
Prep football preview: Indians positive heading into 2014 season

By Paul Farmer | From Page: B1 | Gallery

Serena Williams beats American teen at US Open

By The Associated Press | From Page: B1

 
Carter’s HR in 8th leads Astros over A’s 4-2

By The Associated Press | From Page: B1 | Gallery

Love struck: Kevin Love pledges commitment to Cavs

By The Associated Press | From Page: B2

 
Sarkisian: USC looking into Shaw’s heroic story

By The Associated Press | From Page: B2

Davis, US men beat Slovenia in basketball exhibition

By The Associated Press | From Page: B2

 
Latest Astrodome proposal: massive indoor park

By The Associated Press | From Page: B2

Bumgarner flirts with perfection, finishes with 1-hitter in Giants win

By The Associated Press | From Page: B2 | Gallery

 
No reason to feel sorry for Jim Furyk

By The Associated Press | From Page: B2

TMS 2015 schedule springs back to night race

By The Associated Press | From Page: B2

 
.

Business

UN health agency urges crackdown on e-cigarettes

By The Associated Press | From Page: B8

 
Survey: US consumer confidence near a 7-year high

By The Associated Press | From Page: B8

Burger King buys, plans expansion of Tim Hortons

By The Associated Press | From Page: B8

 
.

Obituaries

Frank W. Moy Jr.

By Nancy Green | From Page: A4

 
Lyle Cullum

By Nancy Green | From Page: A4, 1 Comment

Gary Allen Person

By Nancy Green | From Page: A4

 
Florentino”Paul” Castaneda Bersola

By Susan Hiland | From Page: A4

Nadine L Wetherell

By Susan Hiland | From Page: A4

 
.

Comics

Sally Forth

By Daily Republic Syndicated Content | From Page: B5

 
Garfield

By Daily Republic Syndicated Content | From Page: B5

Dilbert

By Daily Republic Syndicated Content | From Page: B5

 
For Better or Worse

By Daily Republic Syndicated Content | From Page: B5

Pickles

By Daily Republic Syndicated Content | From Page: B5

 
Get Fuzzy

By Daily Republic Syndicated Content | From Page: B5

Baldo

By Daily Republic Syndicated Content | From Page: B5

 
Blondie

By Daily Republic Syndicated Content | From Page: B5

Beetle Bailey

By Daily Republic Syndicated Content | From Page: B5

 
Peanuts

By Daily Republic Syndicated Content | From Page: B5

Baby Blues

By Daily Republic Syndicated Content | From Page: B5

 
Frank and Ernest

By Daily Republic Syndicated Content | From Page: B5

Zits

By Daily Republic Syndicated Content | From Page: B5

 
Rose is Rose

By Daily Republic Syndicated Content | From Page: B5

B.C.

By Daily Republic Syndicated Content | From Page: B5

 
Wizard of Id

By Daily Republic Syndicated Content | From Page: B5

Sudoku

By Daily Republic Syndicated Content | From Page: B6

 
Crossword

By Daily Republic Syndicated Content | From Page: B6

Word Sleuth

By Daily Republic Syndicated Content | From Page: B6

 
Cryptoquote

By Daily Republic Syndicated Content | From Page: B6

Bridge

By Daily Republic Syndicated Content | From Page: B6